NASDAQ:CHMA - Chiasma Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $5.94 +0.10 (+1.71 %) (As of 04/21/2019 10:31 AM ET)Previous Close$5.94Today's Range$5.76 - $5.9652-Week Range$1.20 - $7.19Volume114,508 shsAverage Volume218,516 shsMarket Capitalization$145.35 millionP/E RatioN/ADividend YieldN/ABeta1.49 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Chiasma, Inc., a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Waltham, Massachusetts. Receive CHMA News and Ratings via Email Sign-up to receive the latest news and ratings for CHMA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CHMA Previous Symbol CUSIPN/A CIK1339469 Webwww.chiasmapharma.com Phone617-928-5300Debt Debt-to-Equity RatioN/A Current Ratio2.17 Quick Ratio2.17Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.40 per share Price / Book4.24Profitability EPS (Most Recent Fiscal Year)($1.28) Net Income$-31,260,000.00 Net MarginsN/A Return on Equity-69.51% Return on Assets-53.35%Miscellaneous EmployeesN/A Outstanding Shares24,470,000Market Cap$145.35 million Next Earnings Date5/9/2019 (Estimated) OptionableNot Optionable Chiasma (NASDAQ:CHMA) Frequently Asked Questions What is Chiasma's stock symbol? Chiasma trades on the NASDAQ under the ticker symbol "CHMA." How were Chiasma's earnings last quarter? Chiasma Inc (NASDAQ:CHMA) announced its earnings results on Friday, March, 8th. The biotechnology company reported ($0.32) EPS for the quarter, meeting analysts' consensus estimates of ($0.32). View Chiasma's Earnings History. When is Chiasma's next earnings date? Chiasma is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Chiasma. What price target have analysts set for CHMA? 4 analysts have issued 1 year price targets for Chiasma's stock. Their forecasts range from $5.84 to $16.00. On average, they expect Chiasma's stock price to reach $10.9467 in the next twelve months. This suggests a possible upside of 84.3% from the stock's current price. View Analyst Price Targets for Chiasma. What is the consensus analysts' recommendation for Chiasma? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chiasma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chiasma. Has Chiasma been receiving favorable news coverage? Media coverage about CHMA stock has trended somewhat positive on Sunday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Chiasma earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. Who are some of Chiasma's key competitors? Some companies that are related to Chiasma include Aurinia Pharmaceuticals (AUPH), Crinetics Pharmaceuticals (CRNX), Odonate Therapeutics (ODT), Kura Oncology (KURA), OvaScience (OVAS), ZEALAND PHARMA/S (ZEAL), Stemline Therapeutics (STML), Forty Seven (FTSV), Catalyst Pharmaceuticals (CPRX), Synthorx (THOR), Basilea Pharmaceutica (BPMUF), GlycoMimetics (GLYC), Zymeworks (ZYME), Emisphere Technologies (EMIS) and Urogen Pharma (URGN). What other stocks do shareholders of Chiasma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Chiasma investors own include Arbutus Biopharma (ABUS), Bausch Health Companies (BHC), GW Pharmaceuticals PLC- (GWPH), BioDelivery Sciences International (BDSI), Mattel (MAT), Alnylam Pharmaceuticals (ALNY), Ultra Clean (UCTT), General Electric (GE), GoPro (GPRO) and Progenics Pharmaceuticals (PGNX). Who are Chiasma's key executives? Chiasma's management team includes the folowing people: Mr. Mark J. Fitzpatrick, Pres, CEO, Sec. & Director (Age 56)Mr. Drew Enamait, VP of Fin. & Admin. and Principal Accounting Officer (Age 45)Dr. Gary Patou, Head of Clinical (Age 60)Dr. William H. Ludlam, Sr. VP of Clinical Devel. & Medical Affairs (Age 54) When did Chiasma IPO? (CHMA) raised $76 million in an initial public offering on Thursday, July 16th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. Barclays and Cowen and Company served as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers. Who are Chiasma's major shareholders? Chiasma's stock is owned by a number of of institutional and retail investors. Top institutional investors include Tibra Equities Europe Ltd (0.16%). Company insiders that own Chiasma stock include Mark J Fitzpatrick, Roni Mamluk, Scott Minick and William Ludlam. View Institutional Ownership Trends for Chiasma. Which major investors are buying Chiasma stock? CHMA stock was acquired by a variety of institutional investors in the last quarter, including Tibra Equities Europe Ltd. Company insiders that have bought Chiasma stock in the last two years include Mark J Fitzpatrick, Scott Minick and William Ludlam. View Insider Buying and Selling for Chiasma. How do I buy shares of Chiasma? Shares of CHMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Chiasma's stock price today? One share of CHMA stock can currently be purchased for approximately $5.94. How big of a company is Chiasma? Chiasma has a market capitalization of $145.35 million. The biotechnology company earns $-31,260,000.00 in net income (profit) each year or ($1.28) on an earnings per share basis. What is Chiasma's official website? The official website for Chiasma is http://www.chiasmapharma.com. How can I contact Chiasma? Chiasma's mailing address is 460 Totten Pond Road Suite 530, Waltham MA, 02451. The biotechnology company can be reached via phone at 617-928-5300 or via email at [email protected] MarketBeat Community Rating for Chiasma (NASDAQ CHMA)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 179 (Vote Outperform)Underperform Votes: 185 (Vote Underperform)Total Votes: 364MarketBeat's community ratings are surveys of what our community members think about Chiasma and other stocks. Vote "Outperform" if you believe CHMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CHMA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/21/2019 by MarketBeat.com StaffFeatured Article: What is a Stop Order?